The safety of authorised COVID-19 vaccines is continuously monitored and updated information is regularly provided to the public.
Safety updates outline the outcomes from assessments of emerging worldwide safety data carried out mainly by EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) (section 1). They also outline how safety is monitored and contain high-level information on suspected adverse reaction reports, which PRAC takes into account in its assessments (section 2).
This safety update follows the update of 13 April 2022 and reflects the main assessment outcomes of the PRAC meeting held 02 to 05 May 2022. EMA confirms that the benefits of all currently authorised COVID-19 vaccines continue to outweigh their side effects, given the risk of COVID-19 illness and related complications, including hospitalisation and death…
